ZNF287

Summary

ZNF287 (zinc finger protein 287, HGNC:13502) is a protein-coding gene on chromosome 17p11.2, encoding Zinc finger protein 287 (Q9HBT7). May be involved in transcriptional regulation.

This gene encodes a member of the krueppel family of zinc finger proteins, suggesting a role as a transcription factor. Its specific function has not been determined. This gene is located near the Smith-Magenis syndrome region on chromosome 17.

Source: NCBI Gene 57336 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 65 total
• MANE Select transcript: NM_020653

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13502
Approved symbol	ZNF287
Name	zinc finger protein 287
Location	17p11.2
Locus type	gene with protein product
Status	Approved
Aliases	ZKSCAN13, ZSCAN45
Ensembl gene	ENSG00000141040
Ensembl biotype	protein_coding
Entrez	57336

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000395824, ENST00000395825, ENST00000448349, ENST00000461555, ENST00000498796, ENST00000578303, ENST00000907890, ENST00000907891, ENST00000907892, ENST00000907893

RefSeq mRNA: 6 — MANE Select: NM_020653 NM_001346167, NM_001346168, NM_001346169, NM_001346170, NM_001346171, NM_020653

CCDS: CCDS11179

Canonical transcript exons

ENST00000395825 — 6 exons

Exon	Start	End
ENSE00000946324	16567329	16567929
ENSE00000946325	16566525	16566622
ENSE00000946327	16563146	16563232
ENSE00001013944	16563699	16563825
ENSE00002691491	16568952	16569204
ENSE00003842651	16546954	16553426

Expression profiles

Bgee: expression breadth ubiquitous, 182 present calls, max score 86.17.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.0084 / max 93.5180, expressed in 1439 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164738	4.0084	1439

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.17	gold quality
left adrenal gland cortex	UBERON:0035825	81.28	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.06	gold quality
right adrenal gland	UBERON:0001233	80.62	gold quality
right adrenal gland cortex	UBERON:0035827	80.57	gold quality
left adrenal gland	UBERON:0001234	80.31	gold quality
apex of heart	UBERON:0002098	80.03	gold quality
ventricular zone	UBERON:0003053	79.79	gold quality
cortical plate	UBERON:0005343	79.67	gold quality
adenohypophysis	UBERON:0002196	79.48	gold quality
right atrium auricular region	UBERON:0006631	79.26	gold quality
islet of Langerhans	UBERON:0000006	79.06	gold quality
granulocyte	CL:0000094	78.94	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	78.77	gold quality
stromal cell of endometrium	CL:0002255	78.36	gold quality
adrenal cortex	UBERON:0001235	78.30	gold quality
adrenal tissue	UBERON:0018303	78.02	gold quality
heart left ventricle	UBERON:0002084	77.81	gold quality
ganglionic eminence	UBERON:0004023	77.64	gold quality
adrenal gland	UBERON:0002369	77.34	gold quality
skin of leg	UBERON:0001511	77.02	gold quality
gastrocnemius	UBERON:0001388	76.95	gold quality
cardiac atrium	UBERON:0002081	76.72	gold quality
pituitary gland	UBERON:0000007	76.64	gold quality
cardiac ventricle	UBERON:0002082	76.58	gold quality
muscle of leg	UBERON:0001383	76.49	gold quality
lower esophagus muscularis layer	UBERON:0035833	75.77	gold quality
lower esophagus	UBERON:0013473	75.68	gold quality
skin of abdomen	UBERON:0001416	75.52	gold quality
prefrontal cortex	UBERON:0000451	75.13	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.32

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
IL4
IL5

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp287	ENSMUSG00000005267
rattus_norvegicus	Zfp287	ENSRNOG00000003215
drosophila_melanogaster	CG15269	FBGN0028878

Paralogs (51): WIZ (ENSG00000011451), ZNF416 (ENSG00000083817), MYNN (ENSG00000085274), PRDM4 (ENSG00000110851), PRDM2 (ENSG00000116731), ZBTB17 (ENSG00000116809), ZNF644 (ENSG00000122482), GZF1 (ENSG00000125812), ZNF426 (ENSG00000130818), ZNF697 (ENSG00000143067), ZNF687 (ENSG00000143373), ZNF214 (ENSG00000149050), ZNF547 (ENSG00000152433), ZNF776 (ENSG00000152443), ZNF230 (ENSG00000159882), ZNF222 (ENSG00000159885), ZNF233 (ENSG00000159915), ZNF333 (ENSG00000160961), ZNF319 (ENSG00000166188), ZNF592 (ENSG00000166716), ZNF646 (ENSG00000167395), ZNF507 (ENSG00000168813), ZNF768 (ENSG00000169957), ZNF417 (ENSG00000173480), ZNF408 (ENSG00000175213), ZBTB41 (ENSG00000177888), ZNF223 (ENSG00000178386), ZNF852 (ENSG00000178917), ZNF784 (ENSG00000179922), ZNF572 (ENSG00000180938), ZNF707 (ENSG00000181135), ZNF746 (ENSG00000181220), ZNF467 (ENSG00000181444), ZNF530 (ENSG00000183647), ZNF17 (ENSG00000186272), ZNF527 (ENSG00000189164), ZKSCAN7 (ENSG00000196345), ZNF34 (ENSG00000196378), ZNF774 (ENSG00000196391), ZNF777 (ENSG00000196453)

Protein

Protein identifiers

Zinc finger protein 287 — Q9HBT7 (reviewed: Q9HBT7)

Alternative names: Zinc finger protein with KRAB and SCAN domains 13

All UniProt accessions (2): C9JAV4, Q9HBT7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (6): NP_001333096, NP_001333097, NP_001333098, NP_001333099, NP_001333100, NP_065704* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR003309	SCAN_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR038269	SCAN_sf	Homologous_superfamily
IPR050758	Znf_C2H2-type	Family

Pfam: PF00096, PF01352, PF02023

UniProt features (19 total): zinc finger region 14, domain 2, chain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HBT7-F1	68.17	0.16

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 104 (showing top): TGCGCANK_UNKNOWN, GGGTGGRR_PAX4_03, WCTCNATGGY_UNKNOWN, NAGASHIMA_NRG1_SIGNALING_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, ZWANG_DOWN_BY_2ND_EGF_PULSE, NRF1_Q6, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ZBTB18_TARGET_GENES, MIR4659A_3P_MIR4659B_3P, MIR23A_3P_MIR23B_3P, MIR23C, MIR4753_3P, MIR513A_3P_MIR513C_3P, MIR32_5P

GO Biological Process (4): regulation of cytokine production (GO:0001817), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of DNA-templated transcription (GO:0045893), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872), sequence-specific double-stranded DNA binding (GO:1990837)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of gene expression	2
regulation of DNA-templated transcription	2
DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cytokine production	1
regulation of multicellular organismal process	1
transcription by RNA polymerase II	1
positive regulation of RNA biosynthetic process	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

250 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF287	CCDC74B	Q96LY2	447
ZNF287	CCDC169	A6NNP5	430
ZNF287	CCDC190	Q86UF4	418
ZNF287	CCDC125	Q86Z20	397
ZNF287	ELAPOR2	A8MWY0	386
ZNF287	CENATAC	Q86UT8	376
ZNF287	CCDC171	Q6TFL3	365
ZNF287	ZSWIM4	Q9H7M6	336
ZNF287	PAFAH1B3	Q15102	335
ZNF287	TMEM92	Q6UXU6	323
ZNF287	ZNRF4	Q8WWF5	322
ZNF287	SAMD11	Q96NU1	317
ZNF287	TMEM98	Q9Y2Y6	315
ZNF287	ZNF385D	Q9H6B1	311
ZNF287	ZDHHC23	Q8IYP9	311

IntAct

4 interactions, top by confidence:

A	B	Type	Score
ZNF287	RPS24	psi-mi:“MI:0914”(association)	0.350
ZNF287	TRIM24	psi-mi:“MI:0914”(association)	0.350
ZNF287	TMEM62	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): ZNF287 (Affinity Capture-MS), TRIM24 (Affinity Capture-MS), SCAF4 (Affinity Capture-MS), MPP1 (Affinity Capture-MS), SCAND1 (Affinity Capture-MS), IPO8 (Affinity Capture-MS), SSX2B (Affinity Capture-MS), ZNF24 (Affinity Capture-MS), FAHD2A (Affinity Capture-MS), ZNF445 (Affinity Capture-MS), TRIM28 (Affinity Capture-MS), ZNF287 (Affinity Capture-MS), ZNF287 (Positive Genetic), ZNF287 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A1YEP8, A1YEV9, A1YFW2, A1YG26, A1YG48, A1YG60, A2T6E3, A2T6V8, A2T712, A2T736, A2T7D2, A2T7F4, A2T7L7, A2T812, A6QNZ0, O14709, O15535, O43296, O43309, P10073, P17023, P17097, P49910, Q07231, Q12901, Q15776, Q16670, Q1LZ87, Q3MJ62, Q53GI3, Q571J5, Q5JNZ3, Q5RAE6, Q5RBX0, Q5RCD9, Q5RJ54, Q7Z7L9, Q86W11, Q8IZ26, Q8NF99

Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	54
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1121 predictions. Top by Δscore:

Variant	Effect	Δscore
17:16563695:TTA:T	donor_loss	1.0000
17:16563697:A:AC	donor_gain	1.0000
17:16563697:AC:A	donor_gain	1.0000
17:16563697:ACC:A	donor_gain	1.0000
17:16563698:C:CC	donor_gain	1.0000
17:16563698:CC:C	donor_gain	1.0000
17:16563698:CCC:C	donor_gain	1.0000
17:16563698:CCCA:C	donor_gain	1.0000
17:16563823:TTC:T	acceptor_gain	1.0000
17:16563823:TTCC:T	acceptor_loss	1.0000
17:16563824:TC:T	acceptor_gain	1.0000
17:16563824:TCCTA:T	acceptor_loss	1.0000
17:16563825:CC:C	acceptor_gain	1.0000
17:16563826:C:CC	acceptor_gain	1.0000
17:16566521:TCA:T	donor_loss	1.0000
17:16566522:CA:C	donor_loss	1.0000
17:16566523:A:AC	donor_gain	1.0000
17:16566523:ACT:A	donor_loss	1.0000
17:16566524:C:CA	donor_gain	1.0000
17:16566619:GGAG:G	acceptor_gain	1.0000
17:16566620:GAG:G	acceptor_gain	1.0000
17:16566622:GCTAG:G	acceptor_loss	1.0000
17:16566623:C:CC	acceptor_gain	1.0000
17:16566623:CTAG:C	acceptor_loss	1.0000
17:16553422:CCATT:C	acceptor_gain	0.9900
17:16553423:CATT:C	acceptor_gain	0.9900
17:16553423:CATTC:C	acceptor_gain	0.9900
17:16553424:ATTCT:A	acceptor_loss	0.9900
17:16553425:TT:T	acceptor_gain	0.9900
17:16553426:TC:T	acceptor_loss	0.9900

AlphaMissense

5068 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:16552154:A:G	L663P	1.000
17:16552238:A:G	L635P	1.000
17:16552255:G:C	F629L	1.000
17:16552255:G:T	F629L	1.000
17:16552257:A:G	F629L	1.000
17:16552574:A:G	L523P	1.000
17:16552591:G:C	F517L	1.000
17:16552591:G:T	F517L	1.000
17:16552593:A:G	F517L	1.000
17:16552658:A:G	L495P	1.000
17:16552675:G:C	F489L	1.000
17:16552675:G:T	F489L	1.000
17:16552677:A:G	F489L	1.000
17:16552742:A:G	L467P	1.000
17:16552759:G:C	F461L	1.000
17:16552759:G:T	F461L	1.000
17:16552761:A:G	F461L	1.000
17:16552826:A:G	L439P	1.000
17:16552843:G:C	F433L	1.000
17:16552843:G:T	F433L	1.000
17:16552845:A:G	F433L	1.000
17:16551902:A:G	L747P	0.999
17:16551919:G:C	F741L	0.999
17:16551919:G:T	F741L	0.999
17:16551921:A:G	F741L	0.999
17:16551986:A:G	L719P	0.999
17:16552003:A:C	F713L	0.999
17:16552003:A:T	F713L	0.999
17:16552005:A:G	F713L	0.999
17:16552060:A:C	H694Q	0.999

dbSNP variants (sampled 300 via entrez): RS1000217500 (17:16548726 G>C), RS1000433415 (17:16559051 C>T), RS1000814442 (17:16559952 A>G), RS1001109514 (17:16547118 T>C), RS1001314230 (17:16553013 A>G,T), RS1001490335 (17:16558510 G>C), RS1001566299 (17:16560539 A>G), RS1001600193 (17:16558941 C>T), RS1001807791 (17:16553536 A>C,T), RS1001824182 (17:16559958 T>A), RS1002164293 (17:16553970 G>A), RS1002224464 (17:16559345 T>C), RS1002454431 (17:16553702 A>G), RS1002491786 (17:16557145 C>T), RS1002519983 (17:16566081 C>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	5
trichostatin A	affects cotreatment, decreases expression	3
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
GSK-J4	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	affects cotreatment, increases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
ferrous chloride	decreases expression	1
nickel sulfate	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Panobinostat	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Curcumin	increases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Indomethacin	affects cotreatment, increases expression	1
Nickel	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Potassium Chloride	decreases expression, decreases response to substance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer